Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;26(5):562-567.
doi: 10.1097/MCP.0000000000000716.

Molecular profiling in sarcoidosis

Affiliations
Review

Molecular profiling in sarcoidosis

Nicholas K Arger et al. Curr Opin Pulm Med. 2020 Sep.

Abstract

Purpose of review: Sarcoidosis is a systemic disease characterized by granulomatous inflammation of unknown cause. There is extensive heterogeneity between patients with respect to the number and types of organs involved, disease course, and response to therapy. Recent research in the field has leveraged 'omics' techniques such as transcriptomics to identify important 'molecular profiles' in the disease. These tools may help in identifying clinically useful biomarkers and targets for therapy.

Recent findings: Several studies have used gene expression profiling of predesignated lists or the entire genome to find genes and markers that differentiate sarcoidosis from healthy controls, but only a few have compared sarcoidosis patients based on disease phenotypes and organ involvement. The common gene pathways that have been repeatedly identified include those related to the interferon response, T-cell receptor signaling, and the major histocompatibility complex.

Summary: While the molecular profiling studies to date offer the ability to compare sarcoidosis and health as well as across tissues, further longitudinal studies that include sarcoidosis patients with varying outcomes with respect to organ involvement and response to treatment are needed to identify clinically important phenotypes in the disease that can then be differentiated based on molecular features.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: none

References

    1. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG. 1999;16(2):149–73. - PubMed
    1. Tetikkurt C, Yanardag H, Pehlivan M, Bilir M. Clinical features and prognostic significance of splenic involvement in sarcoidosis. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace. 2017;87(3):893. - PubMed
    1. Dwyer-Lindgren L, Bertozzi-Villa A, Stubbs RW, Morozoff C, Shirude S, Naghavi M, et al. Trends and Patterns of Differences in Chronic Respiratory Disease Mortality Among US Counties, 1980–2014. Jama. 2017;318(12):1136–49. - PMC - PubMed
    1. Swigris JJ, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger D, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. American journal of respiratory and critical care medicine. 2011;183(11):1524–30. - PMC - PubMed
    1. Kirkil G, Lower EE, Baughman RP. Predictors of Mortality in Pulmonary Sarcoidosis. Chest. 2017. - PubMed

Publication types

MeSH terms